[A new approach to etiotropic therapy ARVI in children]

Area of Science:

• Pediatrics
• Virology
• Pharmacology

Background:

• Acute viral respiratory infections (ARVI) are common in children.
• Effective etiotropic therapies for pediatric ARVI are needed.

Purpose of the Study:

• To confirm the efficacy and safety of riamilovir (Triazavirin®) in children aged 12-17 with ARVI.
• To evaluate riamilovir's impact on disease duration and adverse events.

Main Methods:

• A multicenter study involving 269 pediatric patients diagnosed with ARVI.
• Etiology confirmed by PCR; patients enrolled within 36 hours of symptom onset.
• Informed consent obtained from patients and parents/guardians.

Main Results:

• Riamilovir (Triazavirin®) demonstrated efficacy and safety in treating pediatric ARVI.
• A significant decrease in disease duration was observed compared to the control group.
• No serious adverse events were reported during the study.

Conclusions:

• Riamilovir (Triazavirin®) is highly effective, safe, and well-tolerated for treating ARVI in children aged 12-17.
• Clinical practice recommendation for riamilovir as etiotropic therapy in this age group.
• Supports the use of riamilovir for its proven efficacy and safety profile.